Guobang Pharma Ltd banner
G

Guobang Pharma Ltd
SSE:605507

Watchlist Manager
Guobang Pharma Ltd
SSE:605507
Watchlist
Price: 23.92 CNY -1.24%
Market Cap: ¥13.4B

P/E

16.3
Current
9%
More Expensive
vs 3-y average of 14.9

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
16.3
=
Market Cap
¥13.6B
/
Net Income
¥820.8m

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
16.3
=
Market Cap
¥13.6B
/
Net Income
¥820.8m

Valuation Scenarios

Guobang Pharma Ltd is trading above its 3-year average

If P/E returns to its 3-Year Average (14.9), the stock would be worth ¥21.91 (8% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-8%
Maximum Upside
+82%
Average Upside
32%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple 16.3 ¥23.92
0%
3-Year Average 14.9 ¥21.91
-8%
5-Year Average 15.6 ¥22.97
-4%
Industry Average 25.5 ¥37.46
+57%
Country Average 29.6 ¥43.52
+82%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
¥13.6B
/
Jan 2026
¥820.8m
=
16.3
Current
¥13.6B
/
Dec 2026
¥1.3B
=
10.8
Forward
¥13.6B
/
Dec 2027
¥1.4B
=
9.5
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Peer Comparison

All Countries
Close

Market Distribution

Lower than 72% of companies in China
Percentile
28th
Based on 5 557 companies
28th percentile
16.3
Low
0 — 17.1
Typical Range
17.1 — 57.7
High
57.7 —
Distribution Statistics
China
Min 0
30th Percentile 17.1
Median 29.6
70th Percentile 57.7
Max 43 569.3

Guobang Pharma Ltd
Glance View

Market Cap
13.4B CNY
Industry
Pharmaceuticals

Guobang Pharma Ltd. has carved its niche within the pharmaceutical industry as an integrated player blending advanced chemical synthesis with pharmaceutical manufacturing. At its core, the company thrives on the development and production of active pharmaceutical ingredients (APIs), which are crucial components for a multitude of medications. Leveraging a robust research and development framework, Guobang Pharma consistently delivers high-quality APIs to both domestic and international clients, ensuring a steady flow of income. This strategic approach, combining a focus on innovative technology and stringent quality control, positions the company as a reliable partner in the global pharmaceutical supply chain. In addition to API production, Guobang Pharma extends its business model through the formulation and manufacturing of finished pharmaceutical products. By operating across this entire value chain, Guobang can capture a larger slice of the industry's revenue pie. The company’s diversified portfolio not only includes essential medicines but also specialty and generic drugs, allowing it to navigate market shifts and regulatory landscapes adeptly. This vertical integration enhances its competitive advantage by reducing dependency on external suppliers while contributing to its bottom line growth, as it fulfills varied market demands from development to distribution.

Intrinsic Value
23.75 CNY
Overvaluation 1%
Intrinsic Value
Price ¥23.92
G
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett